PharmaTimes | in-depth news, features and insights for the pharmaceutical and healthcare sectors

.tb-grid,.tb-grid>.block-editor-inner-blocks>.block-editor-block-list__layout{display:grid;grid-row-gap:25px;grid-column-gap:25px}.tb-grid-item{background:#d38a03;padding:30px}.tb-grid-column{flex-wrap:wrap}.tb-grid-column>*{width:100%}.tb-grid-column.tb-grid-align-top{width:100%;display:flex;align-content:flex-start}.tb-grid-column.tb-grid-align-center{width:100%;display:flex;align-content:center}.tb-grid-column.tb-grid-align-bottom{width:100%;display:flex;align-content:flex-end}[data-toolset-views-view-pagination-block="b5ee7a93952c82ad8154125da3a7733a"] ul { text-align: center;justify-content: center; } .tb-container .tb-container-inner{width:100%;margin:0 auto} .wp-block-toolset-blocks-container.tb-container[data-toolset-blocks-container="2c43613e993e2394568fe34903b86a0f"] { background:linear-gradient(rgba( 0, 0, 0, 0.13 ),rgba( 0, 0, 0, 0.13 )),   url('https://pharmatimes.com/wp-content/uploads/2023/12/AI.jpg') center center no-repeat;background-size:auto, cover;padding: 25px;min-height: 500px;display:ms-flexbox !important;display:flex !important;-ms-flex-direction:column;flex-direction:column;-ms-flex-pack:center;justify-content:center; } .tb-container .tb-container-inner{width:100%;margin:0 auto} .wp-block-toolset-blocks-container.tb-container[data-toolset-blocks-container="25729c831f4b8caf3a7382396af662f4"] { background: rgba( 110, 110, 110, 0.43 );padding: 15px 25px 15px 25px; } .tb-button{color:#f1f1f1}.tb-button--left{text-align:left}.tb-button--center{text-align:center}.tb-button--right{text-align:right}.tb-button__link{color:inherit;cursor:pointer;display:inline-block;line-height:100%;text-decoration:none !important;text-align:center;transition:all 0.3s ease}.tb-button__link:hover,.tb-button__link:focus,.tb-button__link:visited{color:inherit}.tb-button__link:hover .tb-button__content,.tb-button__link:focus .tb-button__content,.tb-button__link:visited .tb-button__content{font-family:inherit;font-style:inherit;font-weight:inherit;letter-spacing:inherit;text-decoration:inherit;text-shadow:inherit;text-transform:inherit}.tb-button__content{vertical-align:middle;transition:all 0.3s ease}.tb-button__icon{transition:all 0.3s ease;display:inline-block;vertical-align:middle;font-style:normal !important}.tb-button__icon::before{content:attr(data-font-code);font-weight:normal !important}.tb-button__link{background-color:#444;border-radius:0.3em;font-size:1.3em;margin-bottom:0.76em;padding:0.55em 1.5em 0.55em} .tb-button[data-toolset-blocks-button="37dad1b8a003c5dbbfa7f1938d6759a2"] .tb-button__link { background-color: rgba( 255, 255, 255, 0 );color: rgba( 255, 255, 255, 1 );border: 2px solid rgba( 255, 255, 255, 1 );font-weight: bold;color: rgba( 255, 255, 255, 1 ); } .tb-container .tb-container-inner{width:100%;margin:0 auto}h2.tb-heading[data-toolset-blocks-heading="3b7ed8e4afda9e2b6b6174785a4c06c4"]  { font-size: 42px;font-family: Merriweather;font-weight: bold;color: rgba( 255, 255, 255, 1 );text-align: left; }  @media only screen and (max-width: 781px) { .tb-grid,.tb-grid>.block-editor-inner-blocks>.block-editor-block-list__layout{display:grid;grid-row-gap:25px;grid-column-gap:25px}.tb-grid-item{background:#d38a03;padding:30px}.tb-grid-column{flex-wrap:wrap}.tb-grid-column>*{width:100%}.tb-grid-column.tb-grid-align-top{width:100%;display:flex;align-content:flex-start}.tb-grid-column.tb-grid-align-center{width:100%;display:flex;align-content:center}.tb-grid-column.tb-grid-align-bottom{width:100%;display:flex;align-content:flex-end}.tb-container .tb-container-inner{width:100%;margin:0 auto}.tb-container .tb-container-inner{width:100%;margin:0 auto}.tb-button{color:#f1f1f1}.tb-button--left{text-align:left}.tb-button--center{text-align:center}.tb-button--right{text-align:right}.tb-button__link{color:inherit;cursor:pointer;display:inline-block;line-height:100%;text-decoration:none !important;text-align:center;transition:all 0.3s ease}.tb-button__link:hover,.tb-button__link:focus,.tb-button__link:visited{color:inherit}.tb-button__link:hover .tb-button__content,.tb-button__link:focus .tb-button__content,.tb-button__link:visited .tb-button__content{font-family:inherit;font-style:inherit;font-weight:inherit;letter-spacing:inherit;text-decoration:inherit;text-shadow:inherit;text-transform:inherit}.tb-button__content{vertical-align:middle;transition:all 0.3s ease}.tb-button__icon{transition:all 0.3s ease;display:inline-block;vertical-align:middle;font-style:normal !important}.tb-button__icon::before{content:attr(data-font-code);font-weight:normal !important}.tb-button__link{background-color:#444;border-radius:0.3em;font-size:1.3em;margin-bottom:0.76em;padding:0.55em 1.5em 0.55em}.tb-container .tb-container-inner{width:100%;margin:0 auto}  } @media only screen and (max-width: 599px) { .tb-grid,.tb-grid>.block-editor-inner-blocks>.block-editor-block-list__layout{display:grid;grid-row-gap:25px;grid-column-gap:25px}.tb-grid-item{background:#d38a03;padding:30px}.tb-grid-column{flex-wrap:wrap}.tb-grid-column>*{width:100%}.tb-grid-column.tb-grid-align-top{width:100%;display:flex;align-content:flex-start}.tb-grid-column.tb-grid-align-center{width:100%;display:flex;align-content:center}.tb-grid-column.tb-grid-align-bottom{width:100%;display:flex;align-content:flex-end}.tb-container .tb-container-inner{width:100%;margin:0 auto}.tb-container .tb-container-inner{width:100%;margin:0 auto}.tb-button{color:#f1f1f1}.tb-button--left{text-align:left}.tb-button--center{text-align:center}.tb-button--right{text-align:right}.tb-button__link{color:inherit;cursor:pointer;display:inline-block;line-height:100%;text-decoration:none !important;text-align:center;transition:all 0.3s ease}.tb-button__link:hover,.tb-button__link:focus,.tb-button__link:visited{color:inherit}.tb-button__link:hover .tb-button__content,.tb-button__link:focus .tb-button__content,.tb-button__link:visited .tb-button__content{font-family:inherit;font-style:inherit;font-weight:inherit;letter-spacing:inherit;text-decoration:inherit;text-shadow:inherit;text-transform:inherit}.tb-button__content{vertical-align:middle;transition:all 0.3s ease}.tb-button__icon{transition:all 0.3s ease;display:inline-block;vertical-align:middle;font-style:normal !important}.tb-button__icon::before{content:attr(data-font-code);font-weight:normal !important}.tb-button__link{background-color:#444;border-radius:0.3em;font-size:1.3em;margin-bottom:0.76em;padding:0.55em 1.5em 0.55em}.tb-container .tb-container-inner{width:100%;margin:0 auto}  } 

Urban hype

GLP-1s are reshaping the UK and pharma must prepare

News

R1 Therapeutics launches with $77.5m to advance hyperphosphatemia treatment

Mar 17, 2026

Financing and global licensing deal to accelerate phase 2b development of AP306

Taiwan Bio partners with Terumo to advance automated Treg manufacturing

Mar 17, 2026

Collaboration aims to streamline and scale next‑generation Treg therapy production

Elevara begins phase 2b trial of ELV001 in rheumatoid arthritis

Mar 16, 2026

Study to assess oral therapy for patients with inadequate response to TNF inhibitors

Lebrikizumab shows strong results for children with atopic dermatitis

Mar 16, 2026

Phase 3 trial delivers significant skin clearance and symptom improvement

MHRA approves new treatment for severe alopecia areata

Mar 12, 2026

Regulator authorises deuruxolitinib for adults with extensive hair loss

Aplagon doses first patient in phase 2a trial of APAC

Mar 12, 2026

Study aims to advance treatment options for severe peripheral arterial disease

Web Exclusives

Digital calculation

Jul 2, 2024

A broad data-led approach to the future of clinical trials

Food for thought

Jul 1, 2024

Weight loss drugs are the word on the street and it’s getting serious

Staying alive

Jul 1, 2024

The challenge of continuously raising prostate cancer awareness

Voluntary role

Jun 13, 2024

Technology is key to recruiting and retaining clinical trial participants

Magazine

Gene party

Feb 5, 2026

Five genomics trends set to reshape research and care in 2026

Through the looking glass

Feb 4, 2026

Will pharma gets its data work back on track in 2026?

January/February 2026

Jan 30, 2026

The New Year edition looks forward with vim, vigour and vision! We are, after all, in the midst of transformation. In drugs, through development, across trials and amid the melting both of digital and AI. It is – at once – exciting, curious and slightly imposing. In this edition we focus on all the aforementioned themes, and NHS turbulence, predictions for 2026, healthcare comms, the future of GLP-1s, online pharmacies, radiology progress, patient centricity 2.0 and more.